SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN') CEO, Dr Graham Kelly, PhD, was interviewed by Sky News', Helen Dalley about the breakthrough brain cancer drug being developed by Novogen. Novogen is an Australian-US drug discovery company focused on the clinical development of drugs targeting two novel drug targets pertinent to a range of therapeutic indications.
The interview can be viewed at http://goo.gl/PH737R.
About Novogen Limited
Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.
Novogen has two Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on our website: www.novogen.com
For more information please contact:
| Corporate Contact Dr. Graham Kelly Executive Chairman & CEO Novogen Group +61 (0) 2 9472 4100 |
Media Enquiries Cristyn Humphreys Chief Operating Officer Novogen Group +61 (0) 2 9472 4111 |
